What should be monitored during peptide therapy?
Monitoring should be individualized, but common items include the exact medication and route, side effects, treatment response, medication interactions, refill timing, pharmacy instructions, vital signs or glucose context when relevant, and clinician-selected labs when indicated.
Do all peptide therapy patients need lab work?
No single lab schedule applies to every peptide or patient. Some situations may need baseline or follow-up labs, while topical or lower-risk products may need different monitoring. A clinician should decide based on the product, goals, history, symptoms, and risk factors.
How often should online peptide therapy follow-up happen?
Follow-up timing depends on the medication, dose stage, side effects, refill cadence, labs, and health changes. More contact may be needed during titration, after side effects, before dose changes, after missed doses, or when new medications or diagnoses appear.
What monitoring matters for semaglutide or tirzepatide?
Clinicians often review stomach symptoms, hydration, nutrition, weight trend, glucose or diabetes-medication context, gallbladder and pancreatitis warning signs, kidney/dehydration risk, dose tolerability, refill timing, and whether branded or compounded access affects instructions.
What monitoring matters for sermorelin?
Sermorelin discussions may include growth-hormone-axis goals, IGF-1 or other clinician-selected labs, glucose context, sleep and recovery response, side effects, pituitary or cancer history, sports-testing concerns, and whether continuing treatment remains appropriate.
Is a refill questionnaire enough monitoring?
Not by itself if it skips side effects, medication changes, contraindications, pharmacy issues, labs when indicated, and access to a clinician. Safer telehealth should include an escalation path for urgent symptoms and individualized dose or refill decisions.